

# Gilead Fund Commentary

September 30, 2026

## AT A GLANCE

**Manager:** Finny Kuruvilla, MD, PhD

**Fund Objective:** Seeks to provide long-term capital appreciation.

**About the Fund:** A diversified mutual fund representing our “best ideas” for long-term capital appreciation. Historical emphases in small- and mid-cap growth, Health Care and Information Technology.

**Benchmark:** Bloomberg US Mid Cap Growth Index<sup>1</sup>

**Morningstar Category:** US Fund Mid-Cap Growth

**Lipper Category:** Mid-Cap Growth

**Net Assets:** \$3.2 billion

**Inception Date:** July 8, 2008

## GLOSSARY

**IGV:** The iShares Expanded Tech-Software Sector ETF is an exchange-traded fund that seeks to track the investment results of the S&P North American Expanded Technology Software Index.

**S&P 500:** The S&P 500 is an index created by Standard & Poor's of American stocks with the largest market capitalization.

**SOX:** The Philadelphia Semiconductor Index is a modified capitalization-weighted index comprised of companies that are involved in the design, distribution, manufacturing, and sale of semiconductors.

**Eventide Asset Management, LLC**

One International Place, Suite 4210

Boston, MA 02110

877-771-EVEN (3836)

[WWW.EVENTIDEFUNDS.COM](http://WWW.EVENTIDEFUNDS.COM)

**Class I: ETILX | Class A: ETAGX | Class C: ETCGX | Class N: ETGLX**

## Review

In the third quarter of 2026, the Gilead Fund (Class I) underperformed its primary benchmark, Bloomberg US Mid Cap Growth Index, with returns of -7.55% and -4.81%, respectively. Relative to the benchmark, the Fund demonstrated strength in the Industrials and Utilities sectors, while we noted underperformance in the Healthcare and Information Technology sectors.

## Contributors

### Top Five Contributors<sup>2</sup> (%)

**Q3 2026**

| Company                | Ticker | Sector                 | Average Weight | Contribution to Return | Total Return <sup>3</sup> |
|------------------------|--------|------------------------|----------------|------------------------|---------------------------|
| Guardant Health Inc    | GH     | Health Care            | 6.38           | 1.09                   | 18.88                     |
| Xometry Inc            | XMTR   | Information Technology | 6.02           | 0.43                   | 6.56                      |
| Palo Alto Networks Inc | PANW   | Information Technology | 2.45           | 0.38                   | 16.51                     |
| Beta Bionics Inc       | BBNX   | Health Care            | 2.24           | 0.37                   | 21.12                     |
| TransMedics Group Inc  | TMDX   | Health Care            | 1.17           | 0.23                   | 25.64                     |

In the third quarter of 2026, the largest contributors to performance were: Guardant Health Inc, Xometry Inc, Palo Alto Networks Inc, Beta Bionics Inc, and TransMedics Group Inc. Guardant Health continued to see strong momentum across their business with significant upside reported in the second quarter and multiple positive catalysts, including recent commercial coverage updates. Xometry's custom manufacturing marketplace accelerated share gains from embedded enterprise product velocity. Palo Alto Networks posted strong returns as demand grew on the back of security risks identified in hacks involving Mythos and Hugging Face. Beta Bionics saw strong performance as sentiment moved more positive following the approval of their patch pump and a pull forward of launch expectations. TransMedics stock remained volatile and saw solid performance in the third quarter following business stability and stronger-than-expected end market trends early in the quarter.

## Detractors

### Top Five Detractors<sup>2</sup> (%)

**Q3 2026**

| Company                       | Ticker | Sector                 | Average Weight | Contribution to Return | Total Return <sup>3</sup> |
|-------------------------------|--------|------------------------|----------------|------------------------|---------------------------|
| Old Dominion Freight Line Inc | ODFL   | Industrials            | 2.49           | -0.52                  | -19.62                    |
| Collegium Pharmaceutical Inc  | COLL   | Health Care            | 1.23           | -0.58                  | -39.72                    |
| Mirum Pharmaceuticals Inc     | MIRM   | Health Care            | 2.31           | -0.68                  | -26.98                    |
| Generac Holdings Inc          | GNRC   | Industrials            | 2.05           | -0.74                  | -29.32                    |
| Lam Research Corp             | LRCX   | Information Technology | 5.07           | -1.57                  | -24.11                    |

In the third quarter of 2026, the largest detractors to performance were: Old Dominion Freight Line Inc, Collegium Pharmaceutical Inc, Mirum Pharmaceuticals Inc, Generac Holdings Inc, and Lam Research Corp. Old Dominion stock sold off on concerns that higher interest rates and fuel prices would negatively impact demand. Collegium Pharmaceutical lowered guidance due to lower-than-expected pricing of an authorized generic for their legacy Nucynta IR/ER product. Mirum Pharmaceuticals disclosed that the FDA requested a second pivotal study for one of their assets, resulting in price weakness. Generac's planned expansion into Data Center backup gensets has been scrutinized for regulatory and broader AI market concerns. Amid this pullback in AI and memory stocks due to cyclical fears and potential oversupply, Lam Research floundered with its focus on memory.

*Performance is historical and does not guarantee future results.*

## Portfolio Team Outlook

The third quarter was a more challenging environment for US equities. Broad indices posted modest gains after a powerful second quarter, but breadth deteriorated sharply. The equal-weight S&P 500 fell 1.87%, trailing the cap-weighted index by 417 basis points, and only about 25% of index constituents ended the quarter above their 50-day moving averages, versus roughly 64% at the end of June. The Federal Reserve raised rates by 25 basis points in September, its first increase since July 2023, and Treasury yields rose sharply across the curve, with the 10-year and 30-year reaching their highest levels since 2002. Energy was a standout as WTI crude rose 30.1% after the Middle East ceasefire progress of the second quarter broke down. The artificial intelligence (“AI”) trade paused after a historic run, with the SOX declining 11.2% following a gain of more than 230% over the prior six quarters, as security concerns, monetization skepticism, circular-financing scrutiny, and data center backlash made the market more guarded. Software continued its rebound, with IGV rising 17.5%. MedTech, hospitals and biotech also outperformed. Outside of these top-down developments, we are encouraged by continued strong execution among several of our holdings, including record revenue growth, raised guidance, and new regulatory approvals.

The Strategic Growth Strategy (“Strategy”) underperformed during the third quarter.

Underperformance was driven by stock selection, partially offset by a positive contribution from sector allocation. Our structural overweight to Healthcare was a strong contributor as Healthcare was the strongest benchmark sector. However, our Healthcare holdings lagged the sector, resulting in a selection drag as several biopharma holdings fell sharply during the quarter. Information Technology within the benchmark was weak during the quarter and the portfolio trailed the benchmark, primarily driven by a handful of semi-related holdings. Industrials was a bright spot, with positive selection in a sector that fell ~13% within the benchmark. Contributors included high conviction holdings related to cybersecurity and on-demand manufacturing. It is worth noting that while the portfolio gave back some relative performance this quarter, it followed one of the strongest relative quarters in the Strategy’s history. The Strategy retains a strong record year-to-date. In our view much of the pullback reflected a top-down related pause in areas that had been working exceptionally well, rather than a change in the underlying fundamentals of our high-conviction exposures.

Looking forward, we are monitoring geopolitical, macroeconomic, and regulatory developments, including Fed policy, Treasury yields, energy prices, and US trade relations, and will continue to



**Finny Kuruvilla, MD, PhD**  
Co-Chief Investment Officer,  
Senior Portfolio Manager

adjust positioning appropriately. Corporate earnings growth remains robust, and labor-market and consumer spending data have been resilient, which supports the fundamentals of the growth companies we own. We continue to anticipate opportunities for company-specific catalysts within healthcare innovation, as we recognize executing well within Healthcare, the Strategy’s largest active overweight, is critical for its success. We also observe attractive risk-adjusted valuations in the long-duration Technology and Healthcare portions of the Strategy, and we believe a pullback driven by rising rates and shifting AI sentiment, rather than weaker company fundamentals, can create opportunity for long-term investors.

The Strategy remains grounded in the belief that companies with strong competitive advantages in attractive industries run by great management teams that focus on value creation for stakeholders will generate attractive returns for our clients over the long term.

### Trailing Returns<sup>4</sup> (%)

30 Sep 2026

| Eventide Gilead Fund                           | YTD   | 3-mos  | 1-year | 3-year <sup>5</sup> | 5-year <sup>5</sup> | 10-year <sup>5</sup> | Since Inception <sup>5</sup> | Inception Date |
|------------------------------------------------|-------|--------|--------|---------------------|---------------------|----------------------|------------------------------|----------------|
| Class I                                        | 13.54 | -7.55  | 19.23  | 16.16               | 3.19                | 13.08                | 13.77                        | 02/02/2010     |
| Class A without load                           | 13.32 | -7.61  | 18.93  | 15.87               | 2.93                | 12.80                | 14.46                        | 10/28/2009     |
| Class A with 5.75% load <sup>6</sup>           | 6.81  | -12.92 | 12.09  | 13.60               | 1.72                | 12.14                | 14.06                        | 10/28/2009     |
| Class C <sup>6</sup>                           | 12.71 | -7.78  | 18.06  | 15.00               | 2.16                | 11.95                | 13.59                        | 10/28/2009     |
| Class N                                        | 13.39 | -7.60  | 19.01  | 15.93               | 2.98                | 12.85                | 13.23                        | 07/08/2008     |
| <b>Benchmark</b>                               |       |        |        |                     |                     |                      |                              |                |
| Bloomberg US Mid Cap Growth Index <sup>1</sup> | 5.28  | -4.81  | 5.07   | 14.99               | 5.66                | 11.53                | 10.46                        | 07/08/2008     |

**Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836).**

Eventide Gilead Fund expense ratio: Class I: 1.18%; Class A: 1.43%; Class C: 2.18%; Class N: 1.38%.

1. The Bloomberg US Mid Cap Growth Index is a float market-cap-weighted index based on an equal-weighted combination of four factors: earnings yield, valuation, dividend yield, and growth. The constituents consist of the lower 800 in

capitalization of the Bloomberg 1000 Index, which is a float market-cap-weighted benchmark of the 1000 most highly capitalized US companies.

2. Source: Bloomberg PORT Attribution Report. Allocation percentages are subject to change at any time, and should not be considered investment advice.
3. The total return percentage listed is impacted by the Fund's transactions and transacted price levels of the holding during the quarter.
4. The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.
5. Performance figures for periods greater than 1 year are annualized. The indices use an inception date of 07/08/2008.
6. Class A and Class C are also subject to a maximum deferred sales charge of 1.00%. This and other expenses that apply to a continued investment in the Fund are described in the Fund's prospectus.

*The opinions expressed herein are those of the Fund's portfolio management team as of 09/30/2026 and are subject to change. There is no guarantee that such views are correct or that the outlook opinions will come to pass. Specific companies mentioned are for performance attribution informational purposes only and should not be construed as buy or sell advice. Reliance upon the views expressed herein is at the sole discretion of the reader. The Adviser's judgment about the quality and intrinsic value of companies may prove to be incorrect. There is no guarantee that any investment will achieve its objectives, generate positive gains, or avoid losses.*

**Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results.** *The Fund's ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the US Food and Drug Administration. Companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the Industrial Sector carry various risks including, but not limited to, risk related to debt loads, intense competition, and sensitivity to economic cycles. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.*

***This information is for use with concurrent or prior delivery of a fund prospectus, which can be obtained at <https://www.eventideinvestments.com/mutual-funds> or by calling 1-877-771-EVEN (3836). Investors should consider a Fund's investment objectives, risks, charges and expenses carefully before investing or sending money. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.***